Letaplimab represents a distinct clinical strategy for managing complement-mediated conditions. This biologic targets C1q, a critical molecule of the complement cascade, effectively block its initial triggering. https://deannahkeg874871.mpeblog.com/73614969/letaplimab-a-groundbreaking-therapeutic-strategy